Boehringer antes up on a €627.5M deal for rights to Au­ti­fony’s schiz­o­phre­nia drugs

Boehringer In­gel­heim has lined up an op­tion on the schiz­o­phre­nia drugs un­der de­vel­op­ment at GSK spin­out Au­ti­fony, in­clud­ing the lead ther­a­py AUT00206.

Start­ing with a €25 mil­lion up­front fee, with an­oth­er €17.5 mil­lion in near-term mile­stones, Boehringer agreed to pay up to €627.5 mil­lion for glob­al rights to its Kv3 mod­u­la­tors. And af­ter ad­vanc­ing the work on schiz­o­phre­nia, the part­ners want to branch out in­to Frag­ile X and oth­er CNS ail­ments.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.